Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

FAQ

  • What is Moleculin's stock symbol?
  • Our stock is traded on the NASDAQ under the symbol MBRX.

  • When was Moleculin incorporated?
  • July 28, 2015

  • When did Moleculin become a public company?
  • Est. May 25, 2016

  • Where is Moleculin located?
  • 2575 W Bellfort, Suite 333
    Houston TX 77054

  • When is Moleculin's fiscal year end?
  • December 31st

  • Who is Moleculin's transfer agent?
  • VStock Transfer, LLC

  • Who is Moleculin's independent auditor?
  • Grant Thornton LLP

  • Who is Moleculin's outside legal counsel?
  • Schiff Hardin LLP
    Cavas Pavri

  • Whom can I contact for general information about Moleculin?
  • Jon Foster
    Chief Financial Officer
    jfoster@moleculin.com